1. Home
  2. Directory
  3. California
  4. Riverside
  5. General Practice
  6. NPI Profile
  7. Prescriptions 1598836413

STEPHEN G. PROVONSHA MD
Prescription History 1598836413
General Practice in Riverside, CA

NPI Status: Active since November 13, 2006

Contact Information

10800 MAGNOLIA AVE
RIVERSIDE, CA
ZIP 92505
Phone: (909) 353-2000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for STEPHEN G. PROVONSHA MD, an active General Practice specialist practicing in Riverside, CA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 266 documented patient claims. Among these therapy options, the most frequently utilized medication is Nano 2nd Gen Pen Needle, which accounts for 78 claims alone.

Medication Index

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: General Practice
Provider Metrics Summary
Total Claims 47
30-Day Fills 156.5
Days Supply 4,700
CA State Average Benchmarks
Peer Average Claims124.0
Peer Average 30-Day Fills305.1
Peer Average Days Supply9,029
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,086.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.12

State Avg Cost Per Claim

$19.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Naltrexone Hcl

Generic Formulation: Naltrexone HclSpecialty: General Practice
Provider Metrics Summary
Total Claims 21
30-Day Fills 24.9
Days Supply 748
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply754
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $716.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.13

State Avg Cost Per Claim

$56.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent people who have been addicted to certain drugs (opiates) from taking them again. It is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). This medication must not be used in people currently taking opiates, including methadone. Doing so can cause sudden withdrawal symptoms. Naltrexone belongs to a class of drugs known as opiate antagonists. It works in the brain to prevent opiate effects (such as feelings of well-being, pain relief). It also decreases the desire to take opiates. Ask your doctor or pharmacist if you should have naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it. This medication is also used to treat alcohol abuse. It can help people drink less alcohol or stop drinking altogether. It also decreases the desire to drink alcohol when used with a treatment program that includes counseling, support, and lifestyle changes.

Nano 2nd Gen Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: General Practice
Provider Metrics Summary
Total Claims 78
30-Day Fills 126.9
Days Supply 3,803
CA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills64.7
Peer Average Days Supply1,923
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 169.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,433.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.38

State Avg Cost Per Claim

$68.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Ozempic

Generic Formulation: SemaglutideSpecialty: General Practice
Provider Metrics Summary
Total Claims 44
30-Day Fills 47.5
Days Supply 1,366
CA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills62.6
Peer Average Days Supply1,823
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32,405.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$736.49

State Avg Cost Per Claim

$1,314.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

Victoza 2-Pak

Generic Formulation: LiraglutideSpecialty: General Practice
Provider Metrics Summary
Total Claims 44
30-Day Fills 47.1
Days Supply 1,331
CA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills27.2
Peer Average Days Supply791
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 131.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,603.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$718.26

State Avg Cost Per Claim

$990.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

Therapeutic Applications

This medication is used with a doctor-approved exercise, behavior change, and reduced-calorie diet program to help you lose weight. It is used by certain overweight people, such as those who are obese or have weight-related medical problems. Losing weight and keeping it off can lessen the many health risks that come with obesity, including heart disease, diabetes, high blood pressure, and a shorter life. Liraglutide is similar to a natural hormone in your body (incretin). It works by controlling your appetite.

Victoza 3-Pak

Generic Formulation: LiraglutideSpecialty: General Practice
Provider Metrics Summary
Total Claims 32
30-Day Fills 38.0
Days Supply 1,140
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills33.6
Peer Average Days Supply995
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 52.4% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,430.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$950.94

State Avg Cost Per Claim

$1,586.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

Therapeutic Applications

This medication is used with a doctor-approved exercise, behavior change, and reduced-calorie diet program to help you lose weight. It is used by certain overweight people, such as those who are obese or have weight-related medical problems. Losing weight and keeping it off can lessen the many health risks that come with obesity, including heart disease, diabetes, high blood pressure, and a shorter life. Liraglutide is similar to a natural hormone in your body (incretin). It works by controlling your appetite.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like STEPHEN G. PROVONSHA MD provides transparency into local medical care patterns within Riverside, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **General Practice** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.